Skip to main content
. Author manuscript; available in PMC: 2014 Aug 15.
Published in final edited form as: Lancet. 2011 May 28;377(9780):1846–1854. doi: 10.1016/S0140-6736(11)60545-X

Figure 2. Kaplan-Meier curves for overall survival.

Figure 2

Overall survival is shown for assessable patients randomly allocated to erlotinib plus bevacizumab (bevacizumab group) or erlotinib plus placebo (control group). Thep value for overall survival is based on a stratified log-rank test; stratification factors were Eastern Cooperative Oncology Group performance status, smoking history, and sex.